Skip to main content
S&P 5007,801.94-0.22%DOW51,218.90-0.59%NASDAQ27,514.85-0.31%BTC$83,240.00-2.83%ETH$2,554.33-5.29%GOLD$4,139.60-1.13%OIL$88.22-1.36%
Smart Investors Daily
SID Premium
BioCardia, Inc. logo

NASDAQ · BCDA

BioCardia, Inc.

Healthcare · Biotechnology

$1.06

Up+$0.01 (+0.94%)

Updated Oct 7, 2026, 6:26 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
8.58M
P/E ratio
-1,087.96
Dividend yield
0.00%
52-week range
$0.75 – $1.80
Volume
113.42K
Avg. volume
598.12K

Price performance · BCDA

BCDA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

BCDA closed at $1.06 after 21 trading sessions, down 4.50% for the selected period.

Last close
$1.06
Period change
-4.50%
Period low
$1.01
Period high
$1.25
Daily close
View OHLC price history
BCDA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.10$1.1099$1.05$1.06113.42K
Oct 5, 2026$1.06$1.09$1.04$1.09148.93K
Oct 2, 2026$1.04$1.05$1.03$1.0452.54K
Oct 1, 2026$1.0001$1.045$0.99$1.02205.87K
Sep 30, 2026$1.04$1.04$1.0062$1.0199.61K
Sep 29, 2026$1.05$1.07$1.00$1.03117.28K
Sep 28, 2026$1.05$1.09$1.035$1.04159.2K
Sep 25, 2026$1.08$1.08$1.05$1.0553.78K
Sep 24, 2026$1.03$1.0876$1.03$1.07122.51K
Sep 23, 2026$1.03$1.0845$1.03$1.05141.36K
Sep 22, 2026$1.03$1.10$0.9801$1.05498.81K
Sep 21, 2026$1.18$1.19$1.06$1.082.08M
Sep 18, 2026$1.12$1.21$1.1035$1.17170.74K
Sep 17, 2026$1.25$1.2599$1.10$1.11417.29K
Sep 16, 2026$1.24$1.40$1.13$1.251.53M
Sep 15, 2026$1.19$1.29$1.19$1.23519.88K
Sep 14, 2026$1.10$1.23$1.10$1.19595.64K
Sep 11, 2026$1.12$1.14$1.08$1.08137.03K
Sep 10, 2026$1.09$1.105$1.07$1.1079.96K
Sep 9, 2026$1.1108$1.14$1.09$1.1091.02K
Sep 8, 2026$1.09$1.135$1.08$1.11130.31K

Latest BCDA news

The latest Smart Investors Daily articles mentioning BCDA.

Stock researchCompany · Overview

BCDA research

Overview

Company profile and research snapshot.

Company profile

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BCDA recent ratings
DateFirmRatingTarget
Aug 24, 2026HC Wainwright & Co.Buy—
Jun 9, 2026HC Wainwright & Co.Buy—
Sep 22, 2025HC Wainwright & Co.Buy—
Dec 18, 2024HC Wainwright & Co.Buy—
Nov 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart. In May 2026, the Company and FDA met and

Yahoo · Sep 23, 2026

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission

SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones. CardiAMP® Autologous Cell Therapy for Ischemic Heart Failure BioCardia is working towards a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) in Q4 2026. The Company has recently provided detailed

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By